AstraZeneca Bid to Expand Imfinzi’s NSCLC Label Hit with Phase III Flop 11/14/2023

Ipsen, Genfit Build Case for Rare Liver Disease Drug with Phase III Data 11/14/2023

Ajinomoto Targets Gene Therapy Space with $620M Forge Acquisition 11/14/2023

Artificial intelligence (AI) is on the rise. Until now, AI applications generally have "black box" character: How AI arrives at its results remains hidden. Prof. Dr. Jürgen Bajorath, a cheminformatics scientist at the University of Bonn, and his team have developed a method that reveals how certain AI applications work in pharmaceutical research.

Bayer and US-based Recursion Pharmaceuticals, Inc., a clinical stage TechBio company decoding biology to industrialize drug discovery, announced that they have updated the focus of their research collaboration to precision oncology.

The oncology-focused collaboration will leverage Bayer's small molecule compound library and expertise in biology and medicinal chemistry as well as Recursion’s purpose-built artificial intelligence-guided drug discovery platform.

Novo Ends Semaglutide Kidney Study Early Due to Strong Efficacy Signals 10/11/2023

Roche’s Subcutaneous Ocrevus Rivals IV Formulation in Phase III MS Trial 10/11/2023

EU to Order Illumina to Sell Grail After Years of Regulatory Challenges 10/11/2023

Sana Downsizes Staff by 29%, Refocuses on Ex Vivo Cell Therapy Platform 10/11/2023

Biotech Bankruptcies Skyrocket 10/11/2023

Opinion: Big Tech’s Move into Biopharma Could Disrupt the Industry 10/11/2023

Today, the U.S. Food and Drug Administration approved Adzynma, the first recombinant (genetically engineered) protein product indicated for prophylactic (preventive) or on demand enzyme replacement therapy (ERT) in adult and pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP), a rare and life-threatening blood clotting disorder.

An investigational therapy for solid tumors could be especially effective when combined with immunotherapy to target a specific kind of cancer cell, a research team at Duke and Harvard have found.

Led by Lee Zou, Ph.D., chair of Duke’s Department of Pharmacology & Cancer Biology, the researchers focused on the way some cancer cells impede normal DNA repair to fuel tumor formation. This phenomenon is known as defective DNA mismatch repair.

FDA Approves Eli Lilly’s Zepbound for Chronic Weight Management 11/8/2023

Bayer Eyes Break-Up, Management Cuts on Disappointing Q3 Results 11/8/2023

Gilead Q3 Revenue Stagnates, Drops Late-Stage COVID-19 and AML Trials 11/8/2023

Q3 earnings recap: winners, losers & surprises 11/8/2023

Biopharma’s Q3 Earnings Season Sees Mixed Results as Challenges Remain 11/8/2023

Activist Investor Takes $1B Stake in BioMarin Amid CEO Change, Disappointing Sales 11/8/2023

Eisai Sees ‘Dramatic’ Increase in Leqembi Uptake Following Full FDA Approval 11/8/2023